Sort
10,766 grants matching “checkpoint inhibitor”
Novel synthetic lethality strategy for TP53 mutant colorectal cancer
$542,949Christos Fountzilas · Roswell Park Cancer Institute Corp · R37 · FY2025 · CA
Armed nanobodies as anti-infectives and anti-tumor agents
$542,900Hao Wu · Boston Children'S Hospital · R01 · FY2024 · AI
Armed nanobodies as anti-infectives and anti-tumor agents
$542,900Hao Wu · Boston Children'S Hospital · R01 · FY2025 · AI
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma
$542,873Anna C Sorace · University Of Alabama At Birmingham · R01 · FY2024 · CA
Integrated Discovery Pipeline for Tumor Neoantigens
$542,768Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2017 · CA
Engineering ferritin degrader-encapsulated platelets for post-surgical TNBC treatment
$542,721Quanyin Hu · University Of Wisconsin-Madison · R01 · FY2024 · EB
Engineering ferritin degrader-encapsulated platelets for post-surgical TNBC treatment
$542,721Quanyin Hu · University Of Wisconsin-Madison · R01 · FY2025 · EB
Immune Checkpoints in Acute Respiratory Distress Syndrome (IC-ARDS)
$542,628Carmen R Mikacenic · Benaroya Research Inst At Virginia Mason · R01 · FY2023 · HL
Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors
$542,443Michael Karin · University Of California, San Diego · R01 · FY2022 · CA
Highly penetrant and immunogenic mouse models of non-viral HCC that are suitable for evaluation of immune checkpoint inhibitors
$542,443Michael Karin · University Of California, San Diego · R01 · FY2023 · CA
PARP INHIBITORS SYNERGIZE WITH LOSS OF CHECKPOINT CONTROL TO KILL MAMMARY CARCINOMA CELLS
$542,349Virginia Commonwealth University · · FY2010 · Department of Defense
Ablating Liver Metastases with SBRT to Enhance Immune Checkpoint Blockade in Melanoma
$542,305Theodore S Lawrence · University Of Michigan At Ann Arbor · R01 · FY2024 · CA
Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer
$542,252Ming Li · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer
$542,252Ming Li · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer
$542,198Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
$541,958Naoto T Ueno · University Of Hawaii At Manoa · R01 · FY2024 · CA
Integrated Discovery Pipeline for Tumor Neoantigens
$541,899Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2020 · CA
Elucidating genetics of response to immune checkpoint blockade in lung cancer
$541,884Naiyer A Rizvi · Columbia University Health Sciences · R01 · FY2019 · CA
Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitors
$541,844Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2019 · CA
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
$541,414Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
$541,414Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Nanoconjugate delivery of proliferation and checkpoint inhibitors to treat glial tumors
$541,408Julia Y Ljubimova · Cedars-Sinai Medical Center · R01 · FY2019 · CA
Advancing RAS pathway targeted therapy in NF1-MPNST: effects of SHP2 and CDK4/6 inhibitors on the tumor and the tumor immune microenvironment
$541,365Christine Anne Pratilas · Johns Hopkins University · R01 · FY2024 · CA
Utilizing MEK Inhibition to Sensitize Microsatellite Stable Colorectal Cancer to Immune Checkpoint Therapy
$541,043Christopher Hanyoung Lieu · University Of Colorado Denver · R01 · FY2019 · CA
Interrogating the response of the tumor microenvironment to combination immunotherapy using a microfluidic platform
$540,860Albert Folch · University Of Washington · R01 · FY2021 · CA